Updated:
Neovision Capital
Neovision Capital is a principal investment firm focused on early and growth-stage investments in healthcare and pan-entertainment. The firm has made 39...
Neovision Capital
Neovision Capital is a principal investment firm focused on early and growth-stage investments in healthcare and pan-entertainment. The firm has made 39 investments, including a Series E investment in CH Biomedical on June 30, 2025. Neovision Capital has facilitated 4 portfolio exits, with Biostar exiting on October 31, 2024.
General information
Firm type
Private Equity
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
What investment stages does Neovision Capital cover?
The firm's stated mandate spans the full venture lifecycle, from seed and start-up rounds through expansion and late-stage growth. This positions Neovision Capital to enter at formation and follow on through later fundraises, though specific check-size ranges or stage concentrations have not been publicly disclosed.
Who leads investment decisions at the firm?
Neovision Capital has not disclosed its GP bench or investment committee structure. No named principals are available through regulatory filings, press coverage, or the firm's own digital presence, leaving the leadership team entirely opaque to outside allocators.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: